search
Back to results

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Primary Purpose

Acute Pain

Status
Terminated
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
valdecoxib
rofecoxib
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Pain focused on measuring sprains and strains

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients had sustained, no more than 48 hours prior to the first dose of study medication, a first- or second-degree ankle sprain of the lateral ligament, specifically: anterior talofibular ligament and/or posterior talofibular ligament and/or calcaneofibular ligament
  • At presentation, all patients were to have Patient's Assessment of Ankle Pain Visual Analog Scale (VAS) (0-100mm) of ≥45 mm in the orthostatic position on full weight bearing (ie, moderate to severe pain), had a minimum rating of 2 on the Patient's Global Assessment of Ankle Injury and Patient's Assessment of Normal Function/Activity
  • Tthe investigator opinion was that each patient required, and was eligible for, therapy with an anti-inflammatory agent and/or analgesics to control symptoms

Exclusion Criteria:

None reported

Sites / Locations

  • Instituto Ortopedico de Goiania
  • Centro de Traumatologia e Ortopedia
  • Hospital Mãe de Deus
  • Hospital Sao Zacarias
  • Grupo Hospitalar Conceiçao
  • Hospital Geral do Grajau
  • Unifesp - Hsp
  • SECONCI

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Arm 1

Arm 2

Arm Description

Outcomes

Primary Outcome Measures

change from baseline in visual analogue scale (VAS) pain intensity

Secondary Outcome Measures

patient's assessment of ankle pain VAS (0-100 mm)
patient's and physician's global assessment of ankle injury
patient's and physician's satisfaction assessments
patient's assessment of normal function/activity
adverse events, physical examinations, and baseline clinical laboratory values

Full Information

First Posted
March 31, 2008
Last Updated
November 28, 2018
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00657449
Brief Title
A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
Official Title
A Double-blind, Double-dummy, Multicenter Randomized Study Of The Efficacy And The Tolerability Of Valdecoxib 40mg Vs Rofecoxib 50mg In The Symptomatic Treatment Of Patients With Ankle Sprain
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Terminated
Why Stopped
See termination reason in detailed description.
Study Start Date
June 4, 2003 (Actual)
Primary Completion Date
October 1, 2004 (Actual)
Study Completion Date
October 5, 2004 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study compares valdecoxib 40 mg once daily vs. rofecoxib 50 mg one daily in treating the signs and symptoms of acute first- or second-degree ankle sprain. The study also evaluated the disability status, tolerability and safety of these treatments.
Detailed Description
A3471007 terminated early (30Sep2004) due to safety concerns about continued usage of rofecoxib after worldwide withdrawal of rofecoxib by Merck & Co Inc

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain
Keywords
sprains and strains

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Active Comparator
Arm Title
Arm 2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
valdecoxib
Intervention Description
valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
Intervention Type
Drug
Intervention Name(s)
rofecoxib
Intervention Description
rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
Primary Outcome Measure Information:
Title
change from baseline in visual analogue scale (VAS) pain intensity
Time Frame
Day 4
Secondary Outcome Measure Information:
Title
patient's assessment of ankle pain VAS (0-100 mm)
Time Frame
Days 1, 4 and 8
Title
patient's and physician's global assessment of ankle injury
Time Frame
Days 1, 4 and 8
Title
patient's and physician's satisfaction assessments
Time Frame
Day 8
Title
patient's assessment of normal function/activity
Time Frame
Days 1, 4 and 8
Title
adverse events, physical examinations, and baseline clinical laboratory values
Time Frame
Adverse Events: Days 1, 4 and 8; Physical examinations: days 1 and 8; Lab tests: day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients had sustained, no more than 48 hours prior to the first dose of study medication, a first- or second-degree ankle sprain of the lateral ligament, specifically: anterior talofibular ligament and/or posterior talofibular ligament and/or calcaneofibular ligament At presentation, all patients were to have Patient's Assessment of Ankle Pain Visual Analog Scale (VAS) (0-100mm) of ≥45 mm in the orthostatic position on full weight bearing (ie, moderate to severe pain), had a minimum rating of 2 on the Patient's Global Assessment of Ankle Injury and Patient's Assessment of Normal Function/Activity Tthe investigator opinion was that each patient required, and was eligible for, therapy with an anti-inflammatory agent and/or analgesics to control symptoms Exclusion Criteria: None reported
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Instituto Ortopedico de Goiania
City
Goiania
State/Province
Goias
ZIP/Postal Code
74210-030
Country
Brazil
Facility Name
Centro de Traumatologia e Ortopedia
City
Goiania
State/Province
Goiás
Country
Brazil
Facility Name
Hospital Mãe de Deus
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
90880480
Country
Brazil
Facility Name
Hospital Sao Zacarias
City
Rio de Janeiro
State/Province
RJ
Country
Brazil
Facility Name
Grupo Hospitalar Conceiçao
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
91350200
Country
Brazil
Facility Name
Hospital Geral do Grajau
City
São Paulo
State/Province
SP
ZIP/Postal Code
04822-320
Country
Brazil
Facility Name
Unifesp - Hsp
City
São Paulo
ZIP/Postal Code
04063003
Country
Brazil
Facility Name
SECONCI
City
São Paulo
ZIP/Postal Code
05001000
Country
Brazil

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3471007&StudyName=A%20Double-blind%2C%20Double-dummy%2C%20Multicenter%20Randomized%20Study%20Of%20The%20Efficacy%20And%20The%20Tolerability%20Of%20Valdecoxib%2040mg%20Vs%20Rofecoxib%2050mg%20In%20The%20Symptomatic%20Treatment%20Of%20Patients%20With%20Ankle%20Sprain
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

We'll reach out to this number within 24 hrs